Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist
Michael M. Tunney, Peter Wark
Abstract
<h3>Tweetable abstract</h3> <b>Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis results in improved clinical outcomes, but infection and inflammation persist</b>https://bit.ly/3PRaRwZ
Topics & Concepts
IvacaftorCystic fibrosisInflammationMedicineInternal medicineCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesNematode management and characterization studiesLegume Nitrogen Fixing Symbiosis